Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21145706 | 1.00 | POLB (0.47) | POLBKDM4EHTTALDH1A1PTK6 | |
| SCHEMBL21145677 | 0.91 | KDM4E (0.52) | POLBKDM4EHTTALDH1A1PTK6 | |
| SCHEMBL21145676 | 0.91 | KDM4E (0.52) | POLBKDM4EHTTALDH1A1PTK6 | |
| SCHEMBL21145729 | 0.89 | MAPT (0.47) | POLBKDM4EHTTALDH1A1LMNA | |
| SCHEMBL21145731 | 0.89 | MAPT (0.47) | POLBKDM4EHTTALDH1A1LMNA | |
| SCHEMBL21145735 | 0.86 | PTK6 (0.48) | POLBKDM4EALDH1A1PTK6LMNA | |
| SCHEMBL21145737 | 0.86 | PTK6 (0.48) | POLBKDM4EALDH1A1PTK6LMNA | |
| SCHEMBL21145686 | 0.86 | KMT2A (0.50) | POLBKDM4EHTTALDH1A1PTK6 | |
| SCHEMBL21145732 | 0.85 | ATM (0.47) | POLBKDM4EHTTALDH1A1PTK6 | |
| SCHEMBL21145730 | 0.85 | ATM (0.47) | POLBKDM4EHTTALDH1A1PTK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515427-A2 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | Qingdao Primedicine Pharmaceutical Co., Ltd (CN) | 2019-07-31 | — | — | EP | claimed |
| US-11166924-B2 | N-methyl-d-aspartate receptor allosteric modulators and methods for their use | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| US-11166924-B2 | N-methyl-d-aspartate receptor allosteric modulators and methods for their use | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| US-20190216753-A1 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2019-07-18 | — | — | US | disclosed |
| US-20190216753-A1 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216753-A1 | N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE | GRIN2A, GRIN3A, GRIN1 | POLB 3161/4885KDM4E 1424/4885HTT 337/4885 |
| US-11166924-B2 | N-methyl-d-aspartate receptor allosteric modulators and methods for their use | GRIN2A, GRIN3A, GRIN1 | POLB 3161/4885KDM4E 1424/4885HTT 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.